TTM
−$29.46M
YoY change
-13.0%
5Y CAGR
—
Peak year (2006)
−$2.40M
Cumulative net income
−$558.30M
Net Income history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: −$26.86M
Net Income growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: -13.0%
Net Income history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | −$26.86M | -13.0% | +$4.02M | ||
| 2024 | −$30.88M | -17.3% | +$6.46M | ||
| 2023 | −$37.34M | -9.6% | +$3.96M | ||
| 2022 | −$41.30M | +99.5% | −$20.60M | ||
| 2021 | −$20.70M | +23.5% | −$3.94M | ||
| 2020 | −$16.76M | -13.1% | +$2.54M | ||
| 2019 | −$19.29M | -30.3% | +$8.38M | ||
| 2018 | −$27.67M | +16.5% | −$3.92M | ||
| 2017 | −$23.75M | +0.9% | −$205.00K | ||
| 2016 | −$23.55M | -63.1% | +$40.35M | ||
| 2015 | −$63.90M | +74.6% | −$27.30M | ||
| 2014 | −$36.61M | -52.3% | +$40.07M | ||
| 2013 | −$76.68M | +119.3% | −$41.71M | ||
| 2012 | −$34.97M | +204.5% | −$23.48M | ||
| 2011 | −$11.48M | -4.2% | +$508.00K | ||
| 2010 | −$11.99M | -34.8% | +$6.39M | ||
| 2009 | −$18.39M | +27.9% | −$4.01M | ||
| 2008 | −$14.37M | +30.8% | −$3.38M | ||
| 2007 | −$10.99M | +357.0% | −$8.59M | ||
| 2006 | −$2.40M | — | — |
- 2025−$26.86M-13.0%
- 2024−$30.88M-17.3%
- 2023−$37.34M-9.6%
- 2022−$41.30M+99.5%
- 2021−$20.70M+23.5%
- 2020−$16.76M-13.1%
- 2019−$19.29M-30.3%
- 2018−$27.67M+16.5%
- 2017−$23.75M+0.9%
- 2016−$23.55M-63.1%
- 2015−$63.90M+74.6%
- 2014−$36.61M-52.3%
- 2013−$76.68M+119.3%
- 2012−$34.97M+204.5%
- 2011−$11.48M-4.2%
- 2010−$11.99M-34.8%
- 2009−$18.39M+27.9%
- 2008−$14.37M+30.8%
- 2007−$10.99M+357.0%
- 2006−$2.40M—
Net Income values are taken from SELLAS Life Sciences Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at SELLAS Life Sciences Group (SLS)
According to SELLAS Life Sciences Group's latest reported financial statements, the company's current net income (TTM) is −$29.46M. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, SELLAS Life Sciences Group (SLS) reported net income of −$26.86M – declined 13.0% year-over-year.
The record annual net income stands at −$2.40M, reached in 2006; the historical low of −$76.68M was recorded in 2013.
SELLAS Life Sciences Group Net Income by Year
SELLAS Life Sciences Group Net Income 2025: −$26.86M
SELLAS Life Sciences Group net income in 2025 was −$26.86M, declined 13.0% below 2024.
SELLAS Life Sciences Group Net Income 2024: −$30.88M
2024's net income for SELLAS Life Sciences Group came in at −$30.88M, declined 17.3% below 2023.
SELLAS Life Sciences Group Net Income 2023: −$37.34M
SELLAS Life Sciences Group posted net income of −$37.34M in 2023, declined 9.6% below 2022.
SELLAS Life Sciences Group Net Income 2022: −$41.30M
In 2022, SELLAS Life Sciences Group reported net income of −$41.30M, surged 99.5% from 2021.
SELLAS Life Sciences Group Net Income 2021: −$20.70M
SELLAS Life Sciences Group net income in 2021 was −$20.70M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Net Income
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation